These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35044093)

  • 1. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
    Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
    Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.
    Sawa K; Sato I; Takeuchi M; Kawakami K
    Cancer Immunol Immunother; 2023 Mar; 72(3):591-598. PubMed ID: 35994088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
    Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
    Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
    Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
    Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.
    Uchida Y; Kinose D; Nagatani Y; Tanaka-Mizuno S; Nakagawa H; Fukunaga K; Yamaguchi M; Nakano Y
    BMC Cancer; 2022 May; 22(1):551. PubMed ID: 35578210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis.
    Osaki M; Arai T; Sumikawa H; Takimoto T; Takeuchi N; Tamiya A; Okishio K; Inoue Y
    Oncology; 2023; 101(5):303-312. PubMed ID: 36689929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
    Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.